scholarly journals The Tromso Heart Study: serum selenium and risk of myocardial infarction a nested case-control study.

1987 ◽  
Vol 41 (4) ◽  
pp. 329-332 ◽  
Author(s):  
J Ringstad ◽  
B K Jacobsen ◽  
Y Thomassen ◽  
D S Thelle
Keyword(s):  
Myocardial Infarction ◽  
Case Control Study ◽  
Case Control ◽  
Serum Selenium ◽  
Heart Study ◽  
Nested Case Control ◽  
Control Study

scholarly journals OP0234 RISK OF ACUTE MYOCARDIAL INFARCTION AMONG NEW USERS OF CHONDROITIN SULPHATE: A NESTED CASE-CONTROL STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 144.1-144
Author(s):  
R. Mazzucchelli ◽  
S. Rodriguez-Martin ◽  
A. García-Vadillo ◽  
M. Gil ◽  
A. Rodríguez-Miguel ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cardiovascular Disease ◽  
Acute Myocardial Infarction ◽  
Cardiovascular Risk ◽  
Case Control Study ◽  
Chondroitin Sulphate ◽  
Case Control ◽  
Nested Case Control ◽  
Incident Cases ◽  
Control Study

Background:There is some evidence from epidemiological studies suggesting that CS and glucosamine could play a role in cardiovascular disease (CVD) prevention (1-4).Studies to date have included prevalent users, therefore a bias that overestimates protection cannot be excluded.Objectives:To test the hypothesis that chondroitin sulphate (CS) or glucosamine reduce the risk of acute myocardial infarction (AMI).Methods:Case-control study nested in a primary cohort composed of patients aged 40 to 99 years, with at least one year of follow-up in the BIFAP database during the 2002-2015 study period. From this cohort of patients, we identified incident cases of AMI and randomly selected five controls per case, matched by exact age, gender, and index date. Adjusted odds ratios (AOR) and their corresponding 95% confidence interval (CI)) were calculated through a conditional logistic regression. Only new users of CS or glucosamine were considered.Results:A total of 23,585 incident cases of AMI and 117,405 controls were included. The mean age was 67.0 (SD 13.4) years and 71.75% were male, in both groups. 558 (2.37%) cases and 3,082 (2.62%) controls used or had used CS. The current use of CS was associated with a lower risk of AMI (AOR 0.57; 95%CI: 0.46–0.72) and disappeared after discontinuation (recent and past users). The reduced risk among current users was observed in both short-term (<365 days AOR 0.58; 95%CI: 0.45-0.75) and long-term users (>364 days AOR 0.56; 95%CI 0.36-0.87), in both sexes (men, AOR=0.52; 95%CI:0.38-0.70; women, AOR=0.65; 95%CI: 0.46-0.91), in individuals over or under 70 years of age (AOR=0.54; 95%CI:0.38-0.77, and AOR=0.61; 95%CI:0.45-0.82, respectively) and in individuals at intermediate (AOR=0.65; 95%CI:0.48-0.91) and high cardiovascular risk (AOR=0.48;95%CI:0.27-0.83), but not in those at low risk (AOR=1.11; 95%CI:0.48-2.56). In contrast, the current use of glucosamine was not associated with either increased or decreased risk of AMI (AOR= 0.86; CI95% 0.66-1.08)Conclusion:Our results support a cardioprotective effect of CS, while no effect was observed with glucosamine. The highest protection was found among subgroups at higher cardiovascular risk.References:[1]Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365(Journal Article):l1628.[2]de Abajo FJ, Gil MJ, Garcia Poza P, Bryant V, Oliva B, Timoner J, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. PharmacoepidemiolDrug Saf. 2014;23(11):1128–38.[3]Li Z-H, Gao X, Chung VC, Zhong W-F, Fu Q, Lv Y-B, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis. 2020 Apr 6;annrheumdis-2020-217176.[4]King DE, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. 2020 Dec;33(6):842–7.Disclosure of Interests:Ramón Mazzucchelli Speakers bureau: UCB, Lilly, Grant/research support from: Pfizer, Roche, Amgen, Sara Rodriguez-Martin: None declared, Alberto García-Vadillo: None declared, Miguel Gil: None declared, Antonio Rodríguez-Miguel: None declared, Diana Barreira-Hernández: None declared, Alberto García-Lledó: None declared, Francisco de Abajo: None declared

scholarly journals Relation of therapies for ankylosing spondylitis and psoriatic arthritis to risk of myocardial infarction: a nested case control study

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Rachael Stovall ◽  
Christine Peloquin ◽  
David Felson ◽  
Tuhina Neogi ◽  
Maureen Dubreuil
Keyword(s):  
Myocardial Infarction ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Case Control Study ◽  
Tumor Necrosis Factor Inhibitor ◽  
The United States ◽  
Case Control ◽  
Geographical Regions ◽  
Nested Case Control ◽  
Control Study

Abstract Background Risk of myocardial infarction (MI) is elevated in ankylosing spondylitis and psoriatic arthritis (AS/PsA) compared to the general population. We evaluated the risk of MI related to the use of tumor necrosis factor inhibitor (TNFi) and other therapies in AS/PsA. Methods We conducted a nested case-control study using 1994–2018 data from OptumLabs® Data Warehouse, which includes de-identified medical and pharmacy claims, laboratory results, and enrollment records for commercial and Medicare Advantage enrollees. The database contains longitudinal health information on enrollees and patients, representing a diverse mixture of ages, ethnicities and geographical regions across the United States. Assessing AS/PsA separately, MI cases were matched to 4 controls by sex, age, diagnosis year and insurance type. We evaluated treatment within 6 months prior to MI including NSAIDs (AS referent), disease-modifying anti-rheumatic drug (DMARDs; PsA referent) and TNFi alone or in combinations. We evaluated the relation of treatment categories to MI risk using conditional logistical regression adjusting for confounders. Results Among 26,648 AS subjects, there were 237 MI cases and 894 matched controls. Among 43,734 PsA subjects, there were 404 cases and 1596 controls. In AS, relative to NSAID use, the adjusted odds ratio (aOR) for MI among TNFi only users was 0.85 (95% CI 0.39–1.85) and for DMARD only users was 1.04 (95% CI 0.65–1.68). In PsA, relative to DMARD use, the aOR among TNFi only was 1.09 (95% CI 0.74–1.60). Combination therapies also had no effect. Conclusions Among AS/PsA, no combination of therapies appeared to be protective or harmful with regards to MI. Future studies should capture more AS and PsA patients and include longer term follow up to further investigate this question.

scholarly journals Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0204746 ◽  
Author(s):  
Gwen M. C. Masclee ◽  
Huub Straatman ◽  
Andrea Arfè ◽  
Jordi Castellsague ◽  
Edeltraut Garbe ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Case Control Study ◽  
Case Control ◽  
Nested Case Control ◽  
Control Study

Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants

1991 ◽  
Vol 89 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Matti Jauhiainen ◽  
Pekka Koskinen ◽  
Christian Ehnholm ◽  
M.Heikki Frick ◽  
Matti Mänttäri ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Case Control Study ◽  
Disease Risk ◽  
Case Control ◽  
Helsinki Heart Study ◽  
Heart Study ◽  
Study Participants ◽  
Nested Case Control ◽  
Heart Disease Risk ◽  
Control Study

scholarly journals Serum selenium level and cancer risk: a nested case-control study

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Steven A. Narod ◽  
Tomasz Huzarski ◽  
Anna Jakubowska ◽  
Jacek Gronwald ◽  
Cezary Cybulski ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Serum Selenium ◽  
Baseline Serum ◽  
Increased Risk ◽  
Low Selenium ◽  
Nested Case Control ◽  
Risk Of Cancer ◽  
Control Study

Abstract Background Epidemiologic studies have demonstrated a relationship between selenium status and cancer risk among those with low selenium levels. It is of interest to prospectively evaluate the relationship between selenium and cancer among women who reside in a region with ubiquitously low selenium levels. Methods We performed a nested case-control study of baseline serum selenium levels and cancer risk using data and biological samples from 19,573 females that were participants in a biobanking initiative between 2010 and 2014 in Szczecin Poland. Cases included women with any incident cancer (n = 97) and controls (n = 184) were women with no cancer at baseline or follow-up. Serum selenium was quantified using mass spectroscopy. Results The odds ratio associated being below the cutoff of 70.0 μg/L compared to a level above 70.0 μg/L was 2.29 (95% CI 1.26–4.19; P = 0.007). The risks for women in the two middle categories were similar and suggests that the normal range be between 70 μg/L and 90 μg/L. There was evidence for an increased risk of cancer among women in the highest category of selenium levels (i.e., > 90 μg/L), but this association did not achieve statistical significance (OR = 1.63; 95%CI 0.63–4.19; P = 0.31). Conclusions Results from this study suggest that suggest that the optimum serum level of selenium in women living in Poland should be between 70 μg/L and 90 μg/L.

scholarly journals Differential effects of antidepressant subgroups on risk of acute myocardial infarction: A nested case–control study

2020 ◽  
Vol 86 (10) ◽  
pp. 2040-2050
Author(s):  
Rasha Alqdwah‐Fattouh ◽  
Sara Rodríguez‐Martín ◽  
Francisco J. Abajo ◽  
Diana González‐Bermejo ◽  
Miguel Gil ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Case Control Study ◽  
Case Control ◽  
Differential Effects ◽  
Nested Case Control ◽  
Control Study

scholarly journals Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study

2019 ◽  
Vol 8 (12) ◽  
pp. 2150 ◽  
Author(s):  
Sara Rodríguez-Martín ◽  
Francisco J. de Abajo ◽  
Miguel Gil ◽  
Diana González-Bermejo ◽  
Antonio Rodríguez-Miguel ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Case Control Study ◽  
Serum Urate ◽  
Case Control ◽  
Dose Effect ◽  
Duration Of Treatment ◽  
Nested Case Control ◽  
Control Study ◽  
Reduced Risk

Objectives: To test the hypothesis that allopurinol reduces the risk of acute myocardial infarction (AMI) in hyperuricemic patients and to assess whether the effect is dependent on dose, duration and serum uric acid (SUA) level attained after treatment. Methods: Nested case-control study over the period 2002–2015. From a cohort of patients aged 40–99 years old, we identified incident AMI cases and randomly selected five controls per case, matched for exact age, sex and index date. Adjusted odds ratios (AOR) and 95% CI were computed through unconditional logistic regression. Only new users of allopurinol were considered. Results: A total of 4697 AMI cases and 18,919 controls were included. Allopurinol use was associated with a reduced risk of AMI mainly driven by duration of treatment (AOR ≥180 days = 0.71; 95% CI: 0.60–0.84). Among long-term users (≥180 days), the reduced risk was only observed when the SUA level attained was below 7 mg/dL (AOR<6 mg/dL = 0.64; 95% CI: 0.49–0.82; AOR6–7mg/dL = 0.64; 95%CI:0.48-0.84); AOR>7mg/dL = 1.04; 95% CI: 0.75–1.46; p for trend = 0.001). A dose-effect was observed but faded out once adjusted for the SUA level attained. The reduced risk of AMI occurred in both patients with gout and patients with asymptomatic hyperuricemia. Conclusions: The results confirm a cardioprotective effect of allopurinol which is strongly dependent on duration and SUA level attained after treatment.

Sign in / Sign up

Export Citation Format

Share Document